Sou Hu Cai Jing·2026-01-13 12:42Core Insights - Nvidia and Eli Lilly announced a collaboration to invest up to $1 billion over the next five years to establish a research lab focused on AI-assisted drug discovery models [2] - The partnership aims to leverage Nvidia's BioNeMo software platform and Vera Rubin accelerator to develop necessary infrastructure, talent, and computational resources for biological and chemical modeling [2] Group 1: Collaboration Details - The joint innovation lab will be located in the San Francisco Bay Area, bringing together top biologists and chemists from Eli Lilly with Nvidia's software engineers and model developers [2] - Eli Lilly's CEO, David Ricks, emphasized that combining their extensive data and scientific knowledge with Nvidia's computational power could revolutionize drug discovery [2] Group 2: Technology Platforms - BioNeMo is an open-source framework launched by Nvidia in the fall of 2022, specifically designed for building and training deep learning models for drug discovery [4] - The Vera Rubin computing platform, recently unveiled at CES, promises five times the performance of Nvidia's previous Blackwell GPU, providing essential computational power for training new foundational models [3][4] Group 3: Broader Applications - The lab's focus extends beyond AI drug discovery; researchers will also explore AI applications in clinical development, manufacturing, and commercial operations [3] - Eli Lilly is investigating Nvidia's Omniverse robotics platform to optimize manufacturing facilities and increase production of high-demand drugs [3]